Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
Sponsor: Metsera, a wholly owned subsidiary of Pfizer
Summary
This study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related comorbidities excluding T2D. This trial will last for a duration of 84 weeks. The primary endpoint will be assessed after 64 weeks of treatment with the secondary at 84 weeks.
Official title: Evaluating The Efficacy and Safety of MET097, a Fully-Biased, Ultra Long-Acting GLP-1RA, In People With Overweight or Obesity: A Phase 3, Multi-Center Randomized, Controlled Trial (VESPER-4)
Key Details
Gender
All
Age Range
18 Years - 99 Years
Study Type
INTERVENTIONAL
Enrollment
3500
Start Date
2025-12-29
Completion Date
2028-05
Last Updated
2026-02-17
Healthy Volunteers
No
Conditions
Interventions
MET097
Once-weekly MET097 administered via subcutaneous injection
Placebo
Once-weekly placebo administered via subcutaneous injection
Locations (5)
Research Site 97301-001007
Riverside, California, United States
Research Site 97301-001070
Torrance, California, United States
Research Site 97301-001077
Englewood, Colorado, United States
Research Site 97302-001001
Hollywood, Florida, United States
Research Site 97301-001309
Cary, North Carolina, United States